Award type :
Product Development Award
Product Development Award
Product type :
Diagnostics
Diagnostics
Award year :
2021
2021
Project start date :
09 / 27 / 2021
09 / 27 / 2021
Project end date :
09 / 30 / 2022
09 / 30 / 2022
Project duration (months) :
12
12
Development stage :
Early Validation
Early Validation
Target disease :
Visceral Leishmaniasis
Visceral Leishmaniasis
Region served :
India, Nepal Bangladesh
India, Nepal Bangladesh
Recipient organization / Country of funding recipient organization :
Genbody / Republic of Korea
Genbody / Republic of Korea
Collaborator(s) / Country :
Foundation for Innovative New Diagnostics (FIND) / Switzerland
Foundation for Innovative New Diagnostics (FIND) / Switzerland
Funding amount(KRW) :
490,000,000
490,000,000
Despite nearing elimination, visceral leishmaniasis (VL) continues to remain fatal in low resource settings due to the low specificity of currently available VL antibody tests. This project combines new reagents identified by FIND with Genbody’s RDT platform. The preliminary data for the new reagents showed the high accuracy detection of monoclonal antibodies of six Leishmania biomarkers in urine. Using the feasibility study of the antigen detection RDT as well as the prototyping and performance evaluation of the test kit, this project could provide insights into the development of new reagents for the next generation VL diagnostics.